Janux Therapeutics Inc

Janux Therapeutics drops three cancer programs—JANX008, TATE and an EGFR therapy—shifting focus to a leaner oncology pipeline and potential new partnerships.

Janux Therapeutics faces financial hurdles yet holds promise, with TD Cowen’s buy call and a strong immunotherapy focus—discover why investors keep watching.

Janux Therapeutics: immunotherapy‑focused biotech facing steep losses and low stock, yet still promising for cancer treatment—what’s next?

Janux Therapeutics Inc’s stock has experienced a significant drop from its 52-week high, highlighting the high risks and potential rewards of investing in biotech firms, particularly those pioneering in immunotherapy treatments.

Janux Therapeutics’ launch of phase 1b trials for its prostate cancer therapy, JANX007, has sparked significant investor interest, driving a surge in the company’s stock value and solidifying its position as a key player in the biotech sector.